Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy

Journal of the American Society of Nephrology

Volumn 14, Issue 5, 2003, Pages 1234-1253

  Zhang, Guoqiang ^a   Kim, Heungsoo ^a   Cai, Xiaohe ^a   Lopez Guisa, Jesus M ^a   Carmeliet, Peter ^b   Eddy, Allison A ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; CD34 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCAVENGER RECEPTOR; UROKINASE RECEPTOR; VITRONECTIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STAINING; URETER OBSTRUCTION; WILD TYPE;

EID: 0037406922     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000064701.70231.3F     Document Type: Article

References (73)

1. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5: 1273-1287, 1994
2. van Goor H, van der Horst ML, Fidler V, Grond J: Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 66: 564-571, 1992
3. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000
4. Vassalli JD, Sappino AP, Belin D: The plasminogen activator/ plasmin system. J Clin Invest 88: 1067-1072, 1991
5. Rondeau E, Ochi S, Lacave R, He CJ, Medcalf R, Delarue F, Sraer JD: Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int 36: 593-600, 1989
6. Nguyen G, Li X-M, Peraldi M-N, Zacharias U, Hagège J, Rondeau E, Sraer J-D: Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells. Kidney Int 46: 208-215, 1994
7. Almus-Jacobs F, Varki N, Sawdey MS, Loskutoff DJ: Endotoxin stimulates expression of the murine urokinase receptor gene in vivo. Am J Pathol 147: 688-698, 1995
8. Xu Y, Hagege J, Mougenot B, Sraer JD, Rønne E, Rondeau E: Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 50: 2011-2019, 1996
9. Shetty S, Kumar A, Johnson AR, Pueblitz S, Holiday D, Raghu G, Idell S: Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 15: 78-87, 1996
10. Wagner SN, Atkinson MJ, Wagner C, Hofler H, Schmitt M, Wilhelm O: Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem Cell Biol 105: 53-60, 1996
11. Vassalli JD, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92, 1985
12. Preissner KT, Kanse SM, May AE: Urokinase receptor: A molecular organizer in cellular communication. Curr Opin Cell Biol 12: 621-628, 2000
13. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, van der Poll T: Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 59: 2054-2061, 2001
14. Tang WH, Friess H, di Mola FF, Schilling M, Maurer C, Graber HU, Dervenis C, Zimmermann A, Buchler MW: Activation of the serine proteinase system in chronic kidney rejection. Transplantation 65: 1628-1634, 1998
15. Ossowski L, Aguirre-Ghiso JA: Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12: 613-620, 2000
16. Dear AE, Medcalf RL: The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem 252: 185-193, 1998
17. Mondino A, Resnati M, Blasi F: Structure and function of the urokinase receptor. Thromb Haemost 82[Suppl 1]: 19-22, 1999
18. Yebra M, Parry GCN, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA: Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J Biol Chem 271: 29393-29399, 1996
19. Khatib AM, Nip J, Fallavollita L, Lehmann M, Jensen G, Brodt P: Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3. Int J Cancer 91: 300-308, 2001
20. Chapman HA, Wei Y: Protease crosstalk with integrins: The urokinase receptor paradigm. Thromb Haemost 86: 124-129, 2001
21. Preissner KT, Kanse SM, Chavakis T, May AE: The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: Implications for cardiovascular function. Basic Res Cardiol 94: 315-321, 1999
22. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ: Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 165: 1513-1519, 2000
23. Kin Y, Chintala SK, Go Y, Sawaya R, Mohanam S, Kyritsis AP, Rao JS: A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas. Int J Oncol 17: 61-65, 2000
24. Dewerchin M, Van Nuffelen A, Wallays G, Bouché A, Moons L, Carmeliet P, Mulligan RC, Collen D: Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 97: 870-878, 1996
25. Kristensen P, Eriksen J, Blasi F, Dano K: Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 115: 1763-1771, 1991
26. Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S: Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identified to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Com 177: 867-873, 1991
27. Rollins BJ, Morrison ED, Stiles CD: Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 85: 3738-3742, 1988
28. Bijnens AP, Gils A, Knockaert I, Stassen JM, Declerck PJ: Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 275: 6375-6380, 2000
29. Hierck BP, Iperen LV, Gittenberger De Groot AC, Poelmann RE: Modified indirect immunodetection allows study of murine tissue with mouse monoclonal antibodies. J Histochem Cytochem 42: 1499-1502, 1994
30. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571, 1996
31. Kim H, Oda T, Lopez-Guisa J, Wing D, Edwards DR, Soloway PD, Eddy AA: TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 12: 736-748, 2001
32. Eddy AA, Michael AF: Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int 33: 14-23, 1988
33. Zhang G, Oldroyd SD, Huang LH, Yang B, Li Y, Ye R, El Nahas AM: Role of apoptosis and Bcl-2/Bax in the development of tubulointerstitial fibrosis during experimental obstructive nephropathy. Exp Nephrol 9: 71-80, 2001
34. Konda R, Sato H, Sakai K, Sato M, Orikasa S, Kimura N: Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases. Am J Pathol 155: 1587-1597, 1999
35. Oda T, Jung YO, Kim H, Cai x, Lopez-Guisa J, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 30: 587-596, 2001
36. Eddy AA: Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 37[Suppl 2]: 525-529, 2001
37. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT: Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 188: 1029-1037, 1998
38. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA: The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 157: 177-187, 2000
39. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG: Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 185: 963-968, 1997
40. Lan HY, Nikokic-Paterson DJ, Mu W, Atkins RC: Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 48: 753-760, 1995
41. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA: Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 275: 10228-10234, 2000
42. Sitrin RG, Pan PM, Blackwood RA, Huang J, Petty HR: Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J Immunol 166: 4822-4825, 2001
43. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP: Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59: 5307-5314, 1999
44. Xue W, Mizukami I, Todd RF 3rd, Petty HR: Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 57: 1682-1689, 1997
45. Tarui T, Mazar AP, Cines DB, Takada Y: Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 276: 3983-3990, 2001
46. Sitrin RG, Pan PM, Harper HA, Todd RF, 3rd, Harsh DM, Blackwood RA: Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol 165: 3341-3349, 2000
47. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267: 18224-18229, 1992
48. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F: The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 99: 1359-1364, 2002
49. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC: Macrophages, monocyte chemoattractant peptide-1, and TGF-β1 in experimental hydronephrosis. Am J Physiol 226: F926-F933, 1994
50. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, Johnson RJ: Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 56: 571-580, 1999
51. Tuck AB, Hota C, Chambers AF: Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70: 197-204, 2001
52. Alpers CE, Hudkins KL, Floege J, Johnson RJ: Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 5: 201-210, 1994
53. Goumenos DS, Brown CB, Shortland J, El Nahas AM: Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Transplant 9: 1418-1425, 1994
54. Roberts ISD, Burrows C, Shanks JH, Venning M, McWilliam LJ: Intersitial myofibroblasts: Predictors of progression in membranous nephropathy. J Clin Pathol 50: 123-127, 1997
55. Grimm PC, Nickerson P, Jeffery J, Savani RC, Gough J, McKenna RM, Stern E, Rush DN: Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 345: 93-97, 2001
56. Carmeliet P, Moons L, Dewerchin M, Rosenberg S, Herbert JM, Lupu F, Collen D: Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 140: 233-245, 1998
57. Kounnas MZ, Henkin J, Argraves WS, Strickland DK: Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 268: 21862-21867, 1993
58. Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F: alpha-2 Macroglobulin receptor/Ldl receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 131: 1609-1622, 1995
59. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG: Direct Binding of Occupied Urokinase Receptor (uPAR) to LDL Receptor-related Protein Is Required for Endocytosis of uPAR and Regulation of Cell Surface Urokinase Activity. Mol Biol Cell 12: 1467-1479, 2001
60. Herz J, Strickland D: LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108: 779-784, 2001
61. Rajagopal V, Kreitman RJ: Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. J Biol Chem 275: 7566-7573, 2000
62. Vilhardt F, Nielsen M, Sandvig K, van Deurs B: Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells. Mol Biol Cell 10: 179-195, 1999
63. Zhang G, Kim H, Cai X, López-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 14: 1254-1271, 2003
64. Ippoliti R, Lendaro E, Benedetti PA, Torrisi MR, Belleudi F, Carpani D, Soria MR, Fabbrini MS: Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism. FASEB J 14: 1335-1344, 2000
65. Jernigan SM, Eddy AA, eds: Experimental insights into the mechanisms of tubulo-interstitial scarring. In: Mechanisms and Clinical Management of Chronic Renal Failure, edited by El Nahas M, Harris K, Anderson S, Oxford, Oxford University Press, 2000, pp 104-145
66. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388, 1994
67. Reilly JT, Nash JR: Vitronectin (serum spreading factor): Its localisation in normal and fibrotic tissue. J Clin Pathol 41: 1269-1272, 1988
68. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100: 58-67, 1997
69. Panetti TS, McKeown-Longo PJ: The alpha v beta 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 268: 11492-11495, 1993
70. Nip J, Rabbani SA, Shibata HR, Brodt P: Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 95: 2096-2103, 1995
71. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923-928, 1998
72. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A: The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777-784, 2001
73. Brassard DL, Maxwell E, Malkowski M, Nagabhushan TL, Kumar CC, Armstrong L: Integrin alpha(v)beta(3)- mediated activation of apoptosis. Exp Cell Res 251: 33-45, 1999